We are live on ! Find out more
Superstring Capital Management

Superstring Capital Management Portfolio holdings

AUM $200M Turnover 47.73%
1-Year Est. Return 216.62%
This Fund
S&P 500
This Quarter Est. Return
+49.53%
1 Year Est. Return
+216.62%
3 Year Est. Return
+1,109.4%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$140M
AUM Growth
–
Cap. Flow
+$107M
Cap. Flow %
76.62%
Top 10 Hldgs %
70.43%
Holding
30
New
30
Increased
–
Reduced
–
Closed
–
Avg Time Held
0 years
Top 10 Avg Time Held
0 years
Top 20 Avg Time Held
0 years

Top Buys

Rank Stock Value
1
IMGN icon
Immunogen
IMGN
+$11.9M
2
ETNB icon
89bio
ETNB
+$9.39M
3
IONS icon
Ionis Pharmaceuticals
IONS
+$9.08M
4
IDYA icon
IDEAYA Biosciences
IDYA
+$7.5M
5
IMVT icon
Immunovant
IMVT
+$7.49M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow Held Since
IMGN icon
1
DELISTED
Immunogen
IMGN
$17.7M 12.66%
+598,072
New +$11.9M
2023 Q4
0 quarters
CYTK icon
2
Cytokinetics
CYTK
$7.4B
$14.8M 10.58%
+177,603
New +$6.43M
2023 Q4
0 quarters
ETNB icon
3
DELISTED
89bio
ETNB
$11.4M 8.14%
+1,021,477
New +$9.39M
2023 Q4
0 quarters
IONS icon
4
Ionis Pharmaceuticals
IONS
$4.77B
$9.6M 6.85%
+189,618
New +$9.08M
2023 Q4
0 quarters
IDYA icon
5
IDEAYA Biosciences
IDYA
$2.96B
$8.94M 6.38%
+251,295
New +$7.5M
2023 Q4
0 quarters
PTGX icon
6
Protagonist Therapeutics
PTGX
$8.21B
$8.69M 6.21%
+379,143
New +$6.63M
2023 Q4
0 quarters
IMVT icon
7
Immunovant
IMVT
$6.89B
$8.58M 6.12%
+203,592
New +$7.49M
2023 Q4
0 quarters
BBIO icon
8
BridgeBio Pharma
BBIO
$15.1B
$8.33M 5.95%
+206,326
New +$6.2M
2023 Q4
0 quarters
DAWN icon
9
DELISTED
Day One Biopharmaceuticals
DAWN
$5.54M 3.96%
+379,626
New +$4.6M
2023 Q4
0 quarters
MRNS icon
10
DELISTED
Marinus Pharmaceuticals
MRNS
$5.03M 3.59%
+462,444
New +$3.47M
2023 Q4
0 quarters
NBIX icon
11
Neurocrine Biosciences
NBIX
$16.8B
$3.87M 2.76%
+29,346
New +$3.38M
2023 Q4
0 quarters
URGN icon
12
UroGen Pharma
URGN
$1.4B
$3.83M 2.73%
+255,430
New +$3.32M
2023 Q4
0 quarters
SVRA icon
13
Savara
SVRA
$984M
$3.83M 2.73%
+814,266
New +$3.12M
2023 Q4
0 quarters
ROIV icon
14
Roivant Sciences
ROIV
$28B
$3.66M 2.61%
+326,161
New +$3.18M
2023 Q4
0 quarters
LNTH icon
15
Lantheus
LNTH
$6.65B
$3.4M 2.43%
+54,896
New +$3.72M
2023 Q4
0 quarters
FATE icon
16
Fate Therapeutics
FATE
$137M
$3.17M 2.26%
+847,823
New +$2M
2023 Q4
0 quarters
KROS icon
17
Keros Therapeutics
KROS
$197M
$2.97M 2.12%
+74,649
New +$2.34M
2023 Q4
0 quarters
SLRN icon
18
DELISTED
ACELYRIN
SLRN
$2.66M 1.9%
+356,924
New +$3.05M
2023 Q4
0 quarters
VRNA
19
DELISTED
Verona Pharma
VRNA
$2.47M 1.76%
+124,040
New +$1.83M
2023 Q4
0 quarters
NKTX icon
20
Nkarta
NKTX
$86.7M
$2.29M 1.64%
+347,381
New +$900K
2023 Q4
0 quarters
KRYS icon
21
Krystal Biotech
KRYS
$8.77B
$2M 1.42%
+16,086
New +$1.78M
2023 Q4
0 quarters
QTRX icon
22
Quanterix
QTRX
$135M
$1.96M 1.4%
+71,760
New +$1.69M
2023 Q4
0 quarters
AXSM icon
23
Axsome Therapeutics
AXSM
$7.27B
$1.29M 0.92%
+16,179
New +$1.08M
2023 Q4
0 quarters
SY icon
24
So-Young International
SY
$199M
$1M 0.72%
+796,059
New +$880K
2023 Q4
0 quarters
IMTX icon
25
Immatics
IMTX
$946M
$834K 0.6%
+79,213
New +$729K
2023 Q4
0 quarters

Similar funds

Superstring Capital Management's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for Superstring Capital Management, which disclosed 30 positions worth $140M. Its ten largest holdings account for 70% of the portfolio.

Its largest position is Immunogen: 598,072 shares worth $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Superstring Capital Management's largest Q4 2023 buy was Immunogen: 598,072 shares worth $17.7M.
  • Superstring Capital Management's ten largest holdings make up 70% of its $140M portfolio in Q4 2023.
  • Superstring Capital Management disclosed 30 positions in Q4 2023, its first 13F filing on record.

Based on Superstring Capital Management's 13F filing for Q4 2023, filed 14 Feb 2024.